OncoMatch/Clinical Trials/NCT07073547
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Is NCT07073547 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AZD0120 for multiple myeloma.
Treatment: AZD0120 — This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Have received a proteasome inhibitor (PI) as part of their previous therapy
Must have received: immunomodulatory drug
Have received an immunomodulatory drug (IMiD) as part of their previous therapy
Cannot have received: CAR-T cell therapy
Have received prior treatment with CAR T therapy directed at any target
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Phoenix, Arizona
- Research Site · Duarte, California
- Research Site · Denver, Colorado
- Research Site · Tampa, Florida
- Research Site · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify